Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT – Get Free Report) was the recipient of a large drop in short interest during the month of June. As of June 30th, there was short interest totalling 16,200 shares, a drop of 12.9% from the June 15th total of 18,600 shares. Based on an average trading volume of 41,800 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.9% of the shares of the stock are sold short.
Lixte Biotechnology Stock Performance
LIXT stock opened at $2.41 on Tuesday. Lixte Biotechnology has a 1-year low of $1.58 and a 1-year high of $9.50. The company’s 50 day moving average is $2.44 and its 200 day moving average is $2.54.
Lixte Biotechnology (NASDAQ:LIXT – Get Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.43) earnings per share for the quarter.
About Lixte Biotechnology
Lixte Biotechnology Holdings, Inc operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development.
Featured Articles
- Five stocks we like better than Lixte Biotechnology
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Automaker’s Bold Move to an EV Future: Is It Time to Buy Stock?
- Insider Trading – What You Need to Know
- Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Major Gaming Stock to Watch: Why It’s a Safe Bet Now
Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.